Phase 3 Alzheimer's Disease Trial, Recruiting NCT07142954 Sponsor: Eli Lilly and Company Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07142954
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who report that their memory and thinking are not impaired.
  • People who have sufficient reading ability, vision, and hearing to complete memory and thinking tests at the time of screening.

Who may not be able to join:

  • People who have seen a doctor about concerns with their memory.
  • People who have a history of, or have been diagnosed with, impaired memory or thinking, or a significant brain or nervous system condition that can affect cognition.
  • People who are currently enrolled in, or have previously taken part in, any Alzheimer's Disease study that involved an investigational (not yet fully approved) drug.
  • People who are currently using or have previously used prescription medications for mild cognitive impairment or dementia — this includes amyloid-targeting therapies (such as lecanemab, donanemab, or aducanumab), cholinesterase inhibitors (such as benzgalantamine, donepezil, galantamine, or rivastigmine), or memantine.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
25 August 2025
Est. completion
1 July 2033

Where this trial is recruiting

🇯🇵 Japan 🇺🇸 United States

Primary endpoints

Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov